Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

TRAIL Engineering Enhances Expanded Cord Blood NK Cell Anti-Leukemic Activity

Mark Gurney, Margaret Twohig, Derya Goksu Helvaci, Eimear O'Reilly, Sarah Brophy, Janusz Krawczyk, David L. Hermanson, Eva Szegezdi, Michael E. O'Dwyer

Blood (2022) 140 (Supplement 1): 10249–10250.

https://doi.org/10.1182/blood-2022-165517

Published: 2022

Journal Articles

Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia

Daniel J. DeAngelo, Brian A. Jonas, Jane L. Liesveld, Dale L. Bixby, Anjali S. Advani, Paula Marlton, John L. Magnani, Helen M. Thackray, Eric J. Feldman, Michael E. O’Dwyer, Pamela S. Becker

Blood (2022) 139 (8): 1135–1146.

https://doi.org/10.1182/blood.2021010721

Published: 2022

Includes: Supplemental data

Journal Articles

Venetoclax and Epigenetic Modifiers: Promising Novel Combinations for the Treatment of Multiple Myeloma

Lyndsey Flanagan, Michael E. O'Dwyer, Philip Murphy, John Quinn, Siobhan Glavey, Triona Ni Chonghaile

Blood (2021) 138 (Supplement 1): 4703.

https://doi.org/10.1182/blood-2021-147185

Published: 2021

Journal Articles

Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16-Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

Dawn Swan, Michael E. O'Dwyer, Mary Cahill, Janusz Krawczyk, Vitaliy Mykytiv, John Quinn, Robert Henderson, Cian McEllistrim, Andres Hernando, Imelda Parker, Marc Nolan, Elizabeth Lenihan, Eva Szegezdi, Serika D Naicker, Kevin Lynch, Alessandro Natoni, Aideen Ryan, Philip Murphy

Blood (2021) 138 (Supplement 1): 2756.

https://doi.org/10.1182/blood-2021-145530

Published: 2021

Journal Articles

Tc Buster Transposon Engineered CLL-1 CAR-NK Cells Efficiently Target Acute Myeloid Leukemia

Mark Gurney, Eimear O'Reilly, Sarah Corcoran, Sarah Brophy, David Hardwicke, Janusz Krawczyk, David Hermanson, Richard W. Childs, Eva Szegezdi, Michael E. O'Dwyer

Blood (2021) 138 (Supplement 1): 1725.

https://doi.org/10.1182/blood-2021-147244

Published: 2021

Journal Articles

Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA

Blood (2021) 138 (Supplement 1): 4095.

https://doi.org/10.1182/blood-2021-150369

Published: 2021

Journal Articles

Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose

Blood (2021) 138 (Supplement 1): 1646.

https://doi.org/10.1182/blood-2021-146940

Published: 2021

Journal Articles

Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial

Blood (2021) 138 (Supplement 1): 1655.

https://doi.org/10.1182/blood-2021-144421

Published: 2021

Journal Articles

Promising Preliminary Activity of Optimized Affinity, CD38 CAR NK Cells Generated Using a Non-Viral Engineering Approach in Gene Edited Cord Blood Derived NK Cells for the Treatment of Multiple Myeloma

Rohit Duggal, Sumit Sen Santara, Myra Gordon, Aoife Kilgallon, David Hermanson, Richard W. Childs, Michael E. O'Dwyer

Blood (2021) 138 (Supplement 1): 4793.

https://doi.org/10.1182/blood-2021-151379

Published: 2021

Journal Articles

Examining the Usefulness of the Charlson Comorbidity Index to Predict Early Mortality in Patients with Acute Myeloid Leukaemia

Mohamed Bakri Mohamed, Seán R Millar, Vitaliy Mykytiv, Rose McMorrow, Conan Donnelly, Paul M Walsh, Eamonn O'Leary, Nina Orfali, Philip Murphy, Paul V. Browne, John Quinn, Peter O'Gorman, Ruth Clifford, Ezzat El Hassadi, Oonagh Gilligan, Janusz Krawczyk, Michael E. O'Dwyer, Eva Szegezdi, Mary R Cahill

Blood (2021) 138 (Supplement 1): 1218.

https://doi.org/10.1182/blood-2021-149832

Published: 2021

Journal Articles

Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study

Blood (2020) 136 (Supplement 1): 24–26.

https://doi.org/10.1182/blood-2020-134847

Published: 2020

Journal Articles

Integrative Analysis of the Genomic and Transcriptomic Landscape of Relapsed/Refractory Multiple Myeloma Patients Treated With Venetoclax in Combination With Bortezomib and Dexamethasone: Biomarker Analyses From the Phase 3 BELLINI Study

Michael E. O'Dwyer, MD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Shaji K. Kumar, MD, Rakesh Popat, Philippe Moreau, MD, Monique Dail, PhD, Muhammad Jalaluddin, PhD, Xiaoqing Yang, PhD, Xin Lu, Zheng Zha, Fengjiao Dunbar, PhD, Deeksha Vishwamitra, PhD, Christine Mantis, PhD, Amal Melhem-Bertrandt, MD, Jeremy A. Ross, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-134710

Published: 2020

Journal Articles

Hypersialylation Protects Multiple Myeloma Cells from NK Cell-Mediated Immunosurveillance and This Can be Overcome By Targeted Desialylation Using a Sialyltransferase Inhibitor

John Daly, MSc, Subhashis Sarkar, PhD, Alessandro Natoni, PhD, Robert Henderson, MB BCh, Dawn Swan, Mattias Carlsten, MD PhD, Michael E O'Dwyer, MD

Blood (2019) 134 (Supplement_1): 138.

https://doi.org/10.1182/blood-2019-126613

Published: 2019

Journal Articles

T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study

Blood (2019) 134 (Supplement_1): 142.

https://doi.org/10.1182/blood-2019-126094

Published: 2019

Journal Articles

High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan

Daniel J. DeAngelo, MD PhD, Brian A Jonas, MD PhD, Jane L. Liesveld, MD, Dale L. Bixby, MD, Anjali S. Advani, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Michael E O'Dwyer, MD, William E. Fogler, PhD, John L. Magnani, PhD, Mary M Chen, MD PhD, Eric J. Feldman, MD, Helen M Thackray, MD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 2690.

https://doi.org/10.1182/blood-2019-123744

Published: 2019

Journal Articles

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Daniel J. DeAngelo, MD PhD, Harry P. Erba, MD PhD, Brian A Jonas, MD PhD, Michael E O'Dwyer, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Gerwin Huls, MD PhD, Jane L. Liesveld, MD, Brenda Cooper, MD, Bhavana Bhatnagar, DO, Geoffrey L. Uy, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Michael B. Armstrong, MD PhD, William E. Fogler, PhD, Mary M Chen, MD PhD, John L. Magnani, PhD, Helen M Thackray, MD, Eric J. Feldman, MD, Anjali S. Advani, MD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 2650.

https://doi.org/10.1182/blood-2019-123816

Published: 2019

Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia

Blood (2019) 134 (Supplement_1): 1875.

https://doi.org/10.1182/blood-2019-123426

Published: 2019

Journal Articles

Targeting CD38 high Acute Myeloid Leukaemia with "Affinity Optimized" Chimeric Antigen Receptor and Membrane Bound TRAIL Expressing Natural Killer Cells

Emma Nolan, BSc, Arwen Stikvoort, PhD, Mark Gurney, MD, Nutsa Burduli, BSc, Lucy Kirkham-McCarthy, MSc, John Daly, MSc, Niels W. C. J. Van De Donk, Tuna Mutis, MD PhD, Subhashis Sarkar, PhD, Michael E O'Dwyer, MD

Blood (2019) 134 (Supplement_1): 5536.

https://doi.org/10.1182/blood-2019-128605

Published: 2019

Journal Articles

Platelets Preferentially Bind to Myeloma Cells Bearing Sialofucosylated Structures and Protect Them from Natural Killer Cell-Mediated Cytotoxicity

Robert Henderson, MB BCh, Lucy Kirkham-McCarthy, MSc, Dawn Swan, BM BCh, Michael E O'Dwyer, MD, Alessandro Natoni, PhD

Blood (2018) 132 (Supplement 1): 4453.

https://doi.org/10.1182/blood-2018-99-116747

Published: 2018

Journal Articles

The Dual PI3/PIM-Kinase Inhibitor, Ibl-202, Is Highly Synergistic with Venetoclax Against CLL Cells, and TP53 -Knock-out Cells, and Under Conditions That Mimic the Tumor Microenvironment

Yandong Shen, BMedSc (Hon), Kyle R Crassini, MBBS, BSc, Michael E O'Dwyer, MD, Michael Francis O'Neill, PhD BA, Richard Christopherson, PhD Emeritus Professor, Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Oliver Giles Best, PhD BSc

Blood (2018) 132 (Supplement 1): 1870.

https://doi.org/10.1182/blood-2018-99-115574

Published: 2018

NARROW

TRAIL Engineering Enhances Expanded Cord Blood NK Cell Anti-Leukemic Activity

Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia

Venetoclax and Epigenetic Modifiers: Promising Novel Combinations for the Treatment of Multiple Myeloma

Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16-Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

Tc Buster Transposon Engineered CLL-1 CAR-NK Cells Efficiently Target Acute Myeloid Leukemia

Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA

Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose

Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial

Promising Preliminary Activity of Optimized Affinity, CD38 CAR NK Cells Generated Using a Non-Viral Engineering Approach in Gene Edited Cord Blood Derived NK Cells for the Treatment of Multiple Myeloma

Examining the Usefulness of the Charlson Comorbidity Index to Predict Early Mortality in Patients with Acute Myeloid Leukaemia

Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study

Integrative Analysis of the Genomic and Transcriptomic Landscape of Relapsed/Refractory Multiple Myeloma Patients Treated With Venetoclax in Combination With Bortezomib and Dexamethasone: Biomarker Analyses From the Phase 3 BELLINI Study

Hypersialylation Protects Multiple Myeloma Cells from NK Cell-Mediated Immunosurveillance and This Can be Overcome By Targeted Desialylation Using a Sialyltransferase Inhibitor

T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study

High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia

Targeting CD38 high Acute Myeloid Leukaemia with "Affinity Optimized" Chimeric Antigen Receptor and Membrane Bound TRAIL Expressing Natural Killer Cells

Platelets Preferentially Bind to Myeloma Cells Bearing Sialofucosylated Structures and Protect Them from Natural Killer Cell-Mediated Cytotoxicity

The Dual PI3/PIM-Kinase Inhibitor, Ibl-202, Is Highly Synergistic with Venetoclax Against CLL Cells, and TP53 -Knock-out Cells, and Under Conditions That Mimic the Tumor Microenvironment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only